HOTH

HOTH

USD

Hoth Therapeutics Inc. Common Stock

$1.320-0.060 (-4.348%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$1.380

Máximo

$1.410

Mínimo

$1.320

Volumen

0.06M

Fundamentos de la Empresa

Capitalización de Mercado

17.5M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

1.20M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $0.655Actual $1.320Máximo $3.8

Noticias Relacionadas

PR Newswire

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and...

Ver más
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
PR Newswire

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demonstrating >80%...

Ver más
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
PR Newswire

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological,...

Ver más
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
PR Newswire

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for...

Ver más
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.